CDMO, INDENA’S LONG-TERM VISION

MAGAZINE 2023 | January /February 2023

Reflections on War and Peace (1) – A Scenario for a Multipolar W...

by P. Gommers, B. Comanita • March 6, 2023

MAGAZINE 2023 | January /February 2023

How Does Cost Factor into CDMO Selection and Outsourcing Approach?

by K. Hammeke • March 6, 2023

MAGAZINE 2023 | January /February 2023

HPAPI cleaning validation considerations – Part 1

by F. Ohsiek • March 6, 2023

MAGAZINE 2023 | January /February 2023

Small Molecules Approved by the FDA in 2022

by R. Souza • March 6, 2023

MAGAZINE 2023 | January /February 2023

How to Select a Therapeutic Oligonucleotide CDMO

by K. L. Ackley • March 6, 2023

MAGAZINE 2023 | January /February 2023

Panel Discussion on PHARMA SUPPLY CHAIN

by A. Indolese • March 6, 2023

MAGAZINE 2023 | January /February 2023

Ensuring sterile manufacture for EU GMP Annex 1 compliance

by A. Cluet • March 6, 2023

MAGAZINE 2023 | January /February 2023

Drugs and APIs shortage put EU patients at risk

by C. Lusso • March 6, 2023

MAGAZINE 2023 | January /February 2023

Enhancing patient outcomes: Strategies for a post-pandemic Life Scienc...

by F. Stulp • March 6, 2023